advertisement
Abstract #24733 Published in IGR 11-4
Clinical research on treatment of travoprost combined with brinzolamide for primary open angle glaucoma or ocular hypertension
Wang J-P; Zhang D-X; Ma Y; Che X-YInternational Journal of Ophthalmology 2009; 9: 1510-1513
AIM: To study the therapeutic effect and safty of travoprost combined with brinzolamide for primary open angle glaucoma(POAG), ocular hypertension (OHT) and high intraocular pressure after anti-glaucoma surgery. METHODS: Forty-eight cases (52 eyes) with POAG, OHT and high intraocular pressure after anti-glaucoma surgery were subsumed to make a forward-looking, oneway and open study for 2 months. Baseline value of intraocular pressure (IOP) was measured after wash-out period. Then measured IOP, visual acuity and visual field, observed symptoms and signs of eyes and systemic side effects at 2, 4, 8, 12 weeks after treatment. The percentage of patients with IOP (less-than or equal to) 17mmHg was also counted. RESULTS: IOP Baseline value was 28.08 (plus or minus) 2.50mmHg, In 4 follow-up times, IOP was 17.12 (plus or minus) 1.42, 16.71 (plus or minus) 1.55, 16.13 (plus or minus) 1.52 and 16.12 (plus or minus) 1.49mmHg respectively. The mean decrease was 10.35mmHg and the maximum of decreasing rate was 45%. The differences between IOP after treatment and IOP baseline value were statistically significant (P< 0.01). The percentage of patients with IOP (less-than or equal to) 17mmHg was 64%. Common adverse reactions were conjunctival hyperemia, slight burning sensation, mild parageusia and so on, but did not affect cornea, tear film, visual acuity, visual field, blood pressure and heart rate. CONCLUSION: The therapeutic effect and safty of travoprost combined with brinzolamide to reduce IOP were in evidence. LA: Chinese
D.-X. Zhang. Department of Ophthmology, First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. dexiuzhang@mail.xjtu.edu.cn
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
